Two independent studies have reported that the combined use of 1,25(OH)2D3 with different tyrosine kinase inhibitors (TKIs)—gefitinib/erlotinib (epidermal growth factor receptor (EGFR) inhibitors) and sunitinib (multi-target TKI)—induces differentiation of acute myeloid leukemia cells. Here, EGFR is linked to acute myeloid leukemia.